This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2000 Oct;111(1):2-5.

doi: 10.1046/j.1365-2141.2000.02406.x.

Oral iron chelation therapy for thalassaemia: an uncertain scene

M J Pippard¹, D J Weatherall

Affiliations

PMID: 11091177
DOI: 10.1046/j.1365-2141.2000.02406.x

Review

Oral iron chelation therapy for thalassaemia: an uncertain scene

M J Pippard et al. Br J Haematol. 2000 Oct.

. 2000 Oct;111(1):2-5.

doi: 10.1046/j.1365-2141.2000.02406.x.

Authors

M J Pippard¹, D J Weatherall

Affiliation

¹ Department of Molecular and Cellular Pathology, Ninewells Medical School, Dundee, UK.

PMID: 11091177
DOI: 10.1046/j.1365-2141.2000.02406.x

No abstract available

PubMed Disclaimer

Similar articles

Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M, Carrara P, Pinto V, Forni GL. Balocco M, et al. Am J Hematol. 2010 Jun;85(6):460-1. doi: 10.1002/ajh.21711. Am J Hematol. 2010. PMID: 20513129 No abstract available.
Pharmacotherapy of iron overload in thalassaemic patients.
Ceci A, Felisi M, De Sanctis V, De Mattia D. Ceci A, et al. Expert Opin Pharmacother. 2003 Oct;4(10):1763-74. doi: 10.1517/14656566.4.10.1763. Expert Opin Pharmacother. 2003. PMID: 14521486 Review.
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Taher A, et al. Eur J Haematol. 2001 Jul;67(1):30-4. doi: 10.1034/j.1600-0609.2001.067001030.x. Eur J Haematol. 2001. PMID: 11553264 Clinical Trial.
Iron chelation with oral deferiprone in patients with thalassemia.
Stella M, Pinzello G, Maggio A. Stella M, et al. N Engl J Med. 1998 Dec 3;339(23):1712; author reply 1713-4. N Engl J Med. 1998. PMID: 9867539 No abstract available.
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN, El Rassi F, Taher AT. Saliba AN, et al. Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19. Expert Rev Hematol. 2016. PMID: 26613264 Review.

See all similar articles

Cited by

Clinical research: a tale of two studies.
Nathan DG. Nathan DG. Trans Am Clin Climatol Assoc. 2003;114:219-30; discussion 230-2. Trans Am Clin Climatol Assoc. 2003. PMID: 12813922 Free PMC article. Review.
Challenges associated with metal chelation therapy in Alzheimer's disease.
Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, Zatta P. Hegde ML, et al. J Alzheimers Dis. 2009;17(3):457-68. doi: 10.3233/JAD-2009-1068. J Alzheimers Dis. 2009. PMID: 19363258 Free PMC article. Review.
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Fisher SA, et al. Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Cochrane Database Syst Rev. 2013. PMID: 23963793 Free PMC article.
Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives.
Bayanzay K, Alzoebie L. Bayanzay K, et al. J Blood Med. 2016 Aug 8;7:159-69. doi: 10.2147/JBM.S61540. eCollection 2016. J Blood Med. 2016. PMID: 27540317 Free PMC article. Review.
Iron toxicity and chelation therapy.
Britton RS, Leicester KL, Bacon BR. Britton RS, et al. Int J Hematol. 2002 Oct;76(3):219-28. doi: 10.1007/BF02982791. Int J Hematol. 2002. PMID: 12416732 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley